Good evening :)
Place Order
Add to Watchlist

Shilpa Medicare Ltd

SHILPAMED

Shilpa Medicare Ltd

SHILPAMED
Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,997 cr, stock is ranked 742
High RiskStock is 4.77x as volatile as Nifty
460.551.44% (+6.55)
460.551.44% (+6.55)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,997 cr, stock is ranked 742
High RiskStock is 4.77x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,997 cr, stock is ranked 742
High RiskStock is 4.77x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-5,878.912.25
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.915.950.56%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Shilpa Medicare Limited is engaged in the business of manufacturing of bulk drugs or active pharmaceutical ingredient (API) and intermediates, and wind power generation.

Investor Presentation

View older 

Aug 11, 2023

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 5.66%, vs industry avg of 8.36%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.4% to 0.33%

Loading...

Financial YearFY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023TTM
Total Revenue618.60724.00798.83810.50786.96924.85992.111,168.761,067.511,131.33
Raw Materialssubtract327.67374.23418.27313.83256.81293.78329.56390.24404.42916.65
Power & Fuel Costsubtract19.2924.4426.3028.8633.5738.7640.2552.4356.79
Employee Costsubtract82.3091.45127.87149.35176.40196.59235.31264.49287.33
Selling & Administrative Expensessubtract35.2549.3348.3959.0254.50115.69104.32158.09116.52
Operating & Other expensessubtract20.7926.96-2.2682.7984.2643.6511.7780.2886.58
Depreciation/Amortizationsubtract21.4128.6330.6437.2242.0643.7853.9879.8095.50106.94
Interest & Other Itemssubtract4.056.863.132.663.684.5621.8741.1758.6585.35
Taxes & Other Itemssubtract34.1418.3238.9231.5223.4231.9147.2741.60-5.8023.07
EPS9.7813.4613.6813.0213.7719.1518.137.21-3.74-0.08
DPS0.550.600.600.701.001.101.101.100.000.00
Payout ratio0.060.040.040.050.070.060.060.150.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

May 31PDF
Feb 13PDF
FY 2022

Annual report

PDF

Investor Presentation

Feb 10PDF
Oct 29PDF
Aug 14PDF
FY 2023

Annual report

PDF

Investor Presentation

May 25PDF
Feb 15PDF
Nov 13PDF
Aug 12PDF
FY 2024

Annual Report Pending

Investor Presentation

Aug 11PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Shilpa Medicare Ltd-123.082.25
Sun Pharmaceutical Industries Ltd45.896.560.71%
Cipla Ltd43.135.100.57%
Dr Reddy's Laboratories Ltd22.754.400.65%

Price Comparison

Compare SHILPAMED with any stock or ETF
Compare SHILPAMED with any stock or ETF
SHILPAMED
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

High Pledged Promoter Holding

Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding50.01%0.06%0.00%8.52%41.41%

Mar 2023

Jun 2023

Sep 2023

Dec 2023

Shareholding History

SepDec '22MarJunSepDec '2314.46%15.33%13.74%10.26%8.60%8.52%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 4 Mutual Funds holding Shilpa Medicare Ltd




Funds (Top 4)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Plan Growth

Growth
1.2707%1.40%1.40%22/50 (+17)
Motilal Oswal Nifty Microcap 250 Index Fund- Direct- Growth Option

Growth
0.0602%0.30%-0.01%106/255 (+4)
ITI PHARMA AND HEALTHCARE FUND - DIRECT PLAN - GROWTH

Growth
0.0389%0.98%0.98%35/44 (-3)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 19, 2022

Final
Final | Div/Share: ₹1.10

Dividend/Share

1.10

Ex DateEx Date

Sep 19, 2022

Cash Dividend

Ex DateEx DateSep 20, 2021

Final
Final | Div/Share: ₹1.10

Dividend/Share

1.10

Ex DateEx Date

Sep 20, 2021

Cash Dividend

Ex DateEx DateMar 16, 2020

Interim
Interim | Div/Share: ₹1.10

Dividend/Share

1.10

Ex DateEx Date

Mar 16, 2020

Cash Dividend

Ex DateEx DateSep 12, 2019

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 12, 2019

Cash Dividend

Ex DateEx DateMar 1, 2018

Interim
Interim | Div/Share: ₹0.70

Dividend/Share

0.70

Ex DateEx Date

Mar 1, 2018